Circulating endothelial cells are increased in chronic myeloid leukemia blast crisis

Godoy, Carlos; Levy, Débora; Giampaoli, Viviana; Chamone, Dalton F.; Bydlowski, Sérgio Paulo; Pereira, Juliana

doi:10.1590/1414-431x20153646

Cited by 6 publications

(4 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Analysis of the results obtained in the present study showed that a significant increase of ECs was observed in CML patients with blast crisis phase compared to other phases. However, in patients with chronic phase and accelerated phase the number of ECs was slightly increased compared to the control group but the differences were not statistically significant that agreed with Godoy et al [16].…”

Section: Discussionsupporting

confidence: 81%

Angiogenic Activity in Chronic Myeloid Leukemia

Almenshawy¹,

Ibrahim²,

Khalifa³

et al. 2018

J Leuk

View full text Add to dashboard Cite

Objectives: Assessment of angiogenic activity through evaluation of Vascular endothelial growth factor concentration and determination of endothelial cells percentage in the peripheral blood of patients with Chronic myeloid leukemia compared to healthy subjects in order to investigate their role in the pathogenesis and for early detection of the disease progression. Subjects and Methods: Twenty patients with Chronic myeloid leukemia and 15 healthy controls were studied. Evaluation of Vascular endothelial growth factor level in serum was measured by enzyme-linked immunosorbent assay. Determination of circulating endothelial cells percentage expressing CD133 and/or CD34 by flow cytometry in the peripheral blood was also done. Results: The level of Vascular endothelial growth factor was significantly elevated in all groups when compared to controls (p=<0.001). A significant increase of endothelial cells was observed in Chronic myeloid leukemia patients with blast crisis phase compared to other phases (p=<0.001). In patients with chronic phase and accelerated phase the number of endothelial cells was slightly increased compared to the control group but the differences were not statistically significant. Conclusion: The level of Vascular endothelial growth factor was highly elevated in all phases of Chronic myeloid leukemia. While the flow cytometric evaluation of endothelial cell surface markers in the blood of Chronic myeloid leukemia patients can identify a subset of patients with a more aggressive disease course.

show abstract

Section: Discussionsupporting

confidence: 81%

Angiogenic Activity in Chronic Myeloid Leukemia

Almenshawy¹,

Ibrahim²,

Khalifa³

et al. 2018

J Leuk

View full text Add to dashboard Cite

show abstract

“…In many other studies, comparable mean ages were reported, such as 43.4,42, 43.3,48, 52,46, and 55. [9][10][11][12][13][14][15] In the alive group, the mean age was 43.09 ±13.09 ranging from 14-77 years with a median age of 38; in the dead group, the mean age was 37.90 ±14.20 from 3-75 with a median age of 37 years. Significantly lower mean age among the dead group, with the presence of 5 death out of 8 patients in pediatrics age group 3,12,15,16, and17 years.…”

Section: Introductionmentioning

confidence: 99%

Chronic Myeloid Leukemia: A retrospective study of clinical and pathological features

Ahmed

Khaleel

Fadhel

et al. 2022

View full text Add to dashboard Cite

Chronic myeloid leukemia (CML), is one of the myeloproliferative disorders with a characteristic cytogenetic abnormality resulting in the BCR-ABL fusion gene. Imatinib Mesylate is an effective agent for treating patients in all stages of CML. According to the annual Iraqi cancer registry 2019, the total number of chronic myeloproliferative disorders was 338. The percentage and incidence rates were 0.94% and 0.86%, respectively, with a higher incidence rate in males than females (1.12 in males and 0.60 in females). In this registry, no details about CML, so this study aimed to estimate the number of CML patients who attended the national center of hematology from 2005 until 2020 and investigate their epidemiological and clinic-pathological data. All data were obtained from the National Center of Hematology /Baghdad. Data regarding annual admission, number of deaths, and information about age, regions, and sex, were collected from patient cards. Interview and history taking from the patient and reviewing their clinical features at diagnosis were performed, and then statistical analysis was achieved. Two hundred sixteen patients were registered as CML; among them, 163 are still alive, while 53 died. The mean age at diagnosis was 40.39 ±14.30, with a male-to-female ratio of 1:1.16. The pediatrics age group comprises 3.7% of total cases and 1.8 % and 9.4% in the alive and dead groups, respectively. The percentages of death were higher in the pediatric age group, 62,5%( 5 /8), followed by the patient group who were ≥60 years, 42.1%(8/19), while it was the least in adults < 60 years, 21.1% (40/189). In conclusion, the studied patients with CML were younger than the globally reported ages at diagnosis, with predominant female patients. Females had better survival, while children and the elderly were the worse. Most patients were symptomatic at diagnosis; however, a good outcome is achieved when treated with IM. Keywords: CML, Imatinib, leukemia,

show abstract

“…Rigolin et al 47 and Gora-Tybor et al 48 found that higher levels of CECs were identified in patients with chronic lymphocytic leukemia compared to controls. Godoy et al 49 concluded that the number of CECs was increased in chronic myeloid leukemia. All of these researches also used FCM methods to measure CECs and their subpopulations; however, whether our method could be applied to hematologic malignancies such as leukemia remains to be investigated and validated.…”

Section: Discussionmentioning

confidence: 99%

Optimized multiparametric flow cytometric analysis of circulating endothelial cells and their subpopulations in peripheral blood of patients with solid tumors: a technical analysis

Zhou

Yang

et al. 2018

CMAR

View full text Add to dashboard Cite

BackgroundCirculating endothelial cells (CECs) and their subpopulations could be potential novel biomarkers for various malignancies. However, reliable enumerable methods are warranted to further improve their clinical utility. This study aimed to optimize a flow cytometric method (FCM) assay for CECs and subpopulations in peripheral blood for patients with solid cancers.Patients and methodsAn FCM assay was used to detect and identify CECs. A panel of 60 blood samples, including 44 metastatic cancer patients and 16 healthy controls, were used in this study. Some key issues of CEC enumeration, including sample material and anticoagulant selection, optimal titration of antibodies, lysis/wash procedures of blood sample preparation, conditions of sample storage, sufficient cell events to enhance the signal, fluorescence-minus-one controls instead of isotype controls to reduce background noise, optimal selection of cell surface markers, and evaluating the reproducibility of our method, were integrated and investigated. Wilcoxon and Mann–Whitney U tests were used to determine statistically significant differences.ResultsIn this validation study, we refined a five-color FCM method to detect CECs and their subpopulations in peripheral blood of patients with solid tumors. Several key technical issues regarding preanalytical elements, FCM data acquisition, and analysis were addressed. Furthermore, we clinically validated the utility of our method. The baseline levels of mature CECs, endothelial progenitor cells, and activated CECs were higher in cancer patients than healthy subjects (P<0.01). However, there was no significant difference in resting CEC levels between healthy subjects and cancer patients (P=0.193).ConclusionWe integrated and comprehensively addressed significant technical issues found in previously published assays and validated the reproducibility and sensitivity of our proposed method. Future work is required to explore the potential of our optimized method in clinical oncologic applications.

show abstract

Circulating endothelial cells are increased in chronic myeloid leukemia blast crisis

Cited by 6 publications

References 19 publications

Angiogenic Activity in Chronic Myeloid Leukemia

Angiogenic Activity in Chronic Myeloid Leukemia

Chronic Myeloid Leukemia: A retrospective study of clinical and pathological features

Optimized multiparametric flow cytometric analysis of circulating endothelial cells and their subpopulations in peripheral blood of patients with solid tumors: a technical analysis

Contact Info

Product

Resources

About